HEK293-CLDN6 Cells
2 622,00 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. HEK293-CLDN6 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human claudin-6 (CLDN6), a tight junction-associated transmembrane protein belonging to the claudin family. CLDN6 is normally expressed during embryonic and fetal development but is largely absent in most healthy adult tissues, making it an attractive oncofetal antigen for targeted cancer therapy. Aberrant re-expression of CLDN6 has been identified in multiple malignancies, including ovarian cancer, testicular germ cell tumors, endometrial cancer, gastric cancer, and certain sarcomas. Stable HEK293-CLDN6 models provide a controlled system for studying CLDN6 biology and evaluating CLDN6-directed therapeutic approaches. HEK293-CLDN6 cells are widely used in oncology research and drug development for characterization of monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, CAR-T cell therapies, and other engineered immune cell platforms targeting CLDN6. The stable recombinant expression system supports quantitative assessment of antigen binding affinity, receptor density, antibody internalization, epitope specificity, and target-dependent cytotoxicity. These cells are also commonly applied in flow cytometry assay development, reporter assays, high-throughput therapeutic screening, and validation of CLDN6-targeted imaging agents. Because HEK293 cells exhibit high transfection efficiency and robust protein expression, they provide a reliable platform for recombinant membrane protein production and standardized assay generation. |
|---|---|
| Organisme | Human |
| Tissu | Fetal Kidney |
| Maladie | Transformed/immortalized; non-tumorigenic (HEK293 background) |
| Applications | CLDN6-targeted antibody and ADC development; CAR-T cell therapy; ADCC/CDC assays; flow cytometry; oncofetal antigen research; ovarian and germ cell tumor therapeutics |
Caractéristiques
| Âge | Fetus |
|---|---|
| Genre | Female |
| Morphologie | Epithelial-like |
| Type de cellule | Epithelial cells |
| Propriétés de croissance | Monolayer, adherent |
Données réglementaires
| Référence | HEK293-CLDN6 (Cytion catalog number 305985) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_D2TL |
| Statut OGM | GMO-S1: This HEK293 cell line contains a CLDN6 expression construct for oncofetal antigen studies and targeted therapy development. This classification applies only within Germany and may differ elsewhere. |
Données biomoléculaires
| Récepteurs exprimés | CLDN6 |
|---|
Manipulation
| Milieu de culture | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. |
| Réactif de dissociation | Trypsin-EDTA |
| Temps de doublement | approx. 24-36 hours |
| Repiquage | For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO2, and change the medium every 2-3 days. |
| Rapport de fractionnement | 1 to 5 |
| Densité de semis | 2 to 4 x 104 cells/cm2 |
| Renouvellement des fluides | 2 to 3 times per week |
| Rétablissement après le dégel | After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere (for adherent cultures) for at least 24 hours. |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|